The Phage Secures Additional Series A Funding to Develop Preventive Healthcare AI Powered by Blood Glucose Foundation Models
Overview of Funding
The Phage Inc. has announced that it has received additional investment for its ongoing Series A round from Genesia Venture Fund 3, managed by Genesia Ventures, Inc. Other participants in this round include Itochu Technology Ventures, Inc., Tokio Marine & Nichido Fire Insurance Co., Ltd., Fukui Capital Partners Co., Ltd., and Vision Incubate Co., Ltd.
About The Phage Inc.
The Phage is a startup that develops AI-driven personalized preventive healthcare services and provides a "Continuous Glucose Foundation Model (CGFM)." In collaboration with research institutions such as Chiba University, the company is developing analytical models utilizing Continuous Glucose Monitoring (CGM) data. Since its establishment in 2021, the company has aimed for the societal implementation of systems that visualize individual metabolic states and assess disease risks.
Purpose of Funding and Future Outlook
The newly raised funds will primarily be allocated to the following three areas:
- Accelerating the expansion of existing personalized prevention businesses
- Strengthening research and development of preventive healthcare AI to suppress the onset of lifestyle-related diseases
- Recruiting diverse talent regardless of nationality, age, or tenure, and strengthening the organization
Looking ahead, the company aims to expand its business as a "pre-symptomatic disease platform" that enables a larger number of people to detect disease risks early. In parallel with this funding round, the company has also agreed to a strategic business partnership with Tokio Marine & Nichido Fire Insurance Co., Ltd., which will accelerate business advancement in the healthcare sector.
List of Investors
- Genesia Ventures, Inc.
- Itochu Technology Ventures, Inc.
- Tokio Marine & Nichido Fire Insurance Co., Ltd.
- Fukui Capital Partners Co., Ltd.
- Vision Incubate Co., Ltd.